Cellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged.

Continue ReadingCellect. On track with its strategic plans; ApoGraft POC final results estimated to be published by mid-2019; sufficient cash to support clinical and preclinical trials; target price unchanged.